In Vivo CAR-T Cell Therapy: Turning the Body into Its Own Cancer-Fighting Factory

 Quick Summary

•      Standard CAR-T cell therapy works, but it's slow, expensive, and requires specialized labs to re-engineer a patient's T cells outside the body.

•      In vivo CAR-T skips the lab entirely: a gene-carrying infusion, usually a lipid nanoparticle or viral vector, reprograms T cells while they're still circulating in the bloodstream.

•      Early in vivo CAR-T clinical trials in 2025 and 2026, including a myeloma study that reported a 100% response rate in 18 patients, are the first real evidence this approach can work in people.

•      Regulators are still deciding how strict the evidence bar should be, and questions about durability and long-term safety remain unresolved.

•      If it succeeds, in vivo CAR-T could make cell therapy something a local oncology clinic can deliver, not just a handful of specialized hospitals.

A Decade-Old Breakthrough with a Persistent Bottleneck

One of the true success stories in contemporary oncology is CAR-T cell therapy (chimeric antigen receptor T cell therapy). It has taken some patients with life-threatening blood cancers to long-term remission since the first approvals in 2017, when treatment failures left many seeking other options. The concept is simple: extract a patient's own T cells, genetically modify them to target a cancer marker, grow them to the trillions and reintroduce them to the body.

Image by National Cancer Institute on Unsplash

The rub has always been in the manner by which that engineering is accomplished. Manufacturing is done in specialized facilities, over weeks, and a single dose can cost several hundred thousand dollars, directly proportional to the high cost of manufacturing cell therapy. There is a recurring need for pre-treatment chemotherapy to create space for the new cells, and a shortage of infrastructure to support the entire process in a limited number of hospitals in the world. The problem with this effective therapy isn't the biology, it's the logistics. That's what in vivo CAR-T, also known as CAR-T without cell manufacturing, aims to eliminate.

Read More Remarkable Breakthrough: Man Unexpectedly Cured of HIV After Stem Cell Transplant

What “In Vivo” Actually Means

So, what is in vivo CAR-T cell therapy, and how does in vivo CAR-T cell therapy work in practice? In vivo is Latin for “within the living” scientists use it to describe anything that happens inside a living organism, as opposed to ex vivo work done outside the body in a lab. Applied to CAR-T, the concept is straightforward even if the engineering is not: instead of extracting T cells and reprogramming them in a facility, doctors deliver the genetic instructions directly into the patient. The T cells get reprogrammed while they're still doing their job in the bloodstream, a process researcher increasingly describe as T cell reprogramming in the body.

Two delivery technologies are furthest along:

•      Lipid nanoparticles (LNPs): the same class of delivery vehicle used in mRNA vaccines, engineered here to target T cells specifically and carry CAR-encoding genetic material into them. In short, it's lipid nanoparticle delivery for CAR-T cells explained through mRNA vaccine delivery technology now being adapted for cancer therapy.

•      Viral vectors: particularly lentiviral vector CAR-T therapy platforms modified so their outer envelope binds selectively to T cells, delivering the CAR gene as the virus infects the cell.

Both approaches aim to do the same thing: get the right genetic payload into T cells, and only T cells, without needing to remove anything from the patient first.

Image by CDC on Unsplash

From Concept to the Clinic

Until recently, in vivo CAR-T was mostly a promising idea in preclinical models, one strand of the broader push toward in vivo gene therapy for cancer. That has changed. Several companies now have candidates in in vivo CAR-T clinical trials, and the early data is the first real test of whether the approach translates from mouse studies to patients.

Kelonia Therapeutics' KLN-1010, a lentiviral-vector therapy targeting BCMA CAR-T multiple myeloma, produced one of the more striking early readouts: in a Phase I study reported at the American Society of Hematology's 2025 meeting, all 18 evaluable patients responded, and none had detectable minimal residual disease a month after treatment. Researchers running the trial, based in Australia, also noted something clinically significant, patients did not need the chemotherapy typically used to clear existing immune cells before treatment, a step called lympho-depletion that adds toxicity to standard CAR-T. It's an early hint at what the future of CAR-T cell therapy without lympho-depletion could look like, and it's already feeding into a wider body of in vivo CAR-T therapy for multiple myeloma trial results.

Umoja Biopharma's CD19 CAR-T lymphoma leukemia candidate, UB-VV111, became one of the first in vivo CAR-T therapies to receive FDA clearance to begin human testing, and it earned Fast Track designation in 2025 for relapsed or refractory large B-cell lymphoma and chronic lymphocytic leukemia. Interius BioTherapeutics has a competing in vivo program also in Phase I trials. Separately, researchers in China have begun a trial of a CD19/BAFF-R in vivo CAR-T therapy for relapsed leukemia and lymphoma, reflecting how quickly the field has expanded beyond a handful of Western biotechs.

None of this amounts to proof yet. These are small, early-phase, mostly single-arm studies, and the number of treated patients worldwide is still in the dozens rather than the hundreds. But it's a meaningful shift from theoretical promise to clinical signal.

Read More Editing the Future: The CRISPR Revolution in Modern Medicine

Why Pharmaceutical Companies Are Paying Attention

The appeal for drug developers is largely economic and operational. If T cells can be reprogrammed with an infusion rather than a manufacturing run, several things change at once and it points toward next-generation CAR-T therapy built for scale:

•      Speed. There's no multi-week wait for engineered cells to be grown and shipped back.

•      Cost. Removing the manufacturing step removes much of what makes current CAR-T therapies expensive, a cost comparison in vivo vs ex vivo CAR-T therapy that increasingly favors the newer approach.

•      Reach. A therapy that doesn't require an on-site cell-manufacturing lab could, in principle, be delivered at community oncology clinics rather than a small number of specialized centers.

•      Re-dosing. Because there's no need to re-collect and re-engineer cells, some in vivo platforms are designed to allow repeat doses if needed, something not really practical with current ex vivo CAR-T.

For an industry that has watched cell therapy remain a niche, high-cost category for nearly a decade, that combination is hard to ignore.

Image by Sangharsh Lohakare on Unsplash

The Open Questions

The excitement comes with real caveats, and researchers in the field are candid about them. 

• Delivery Precision: It is important to deliver the genetic payload into T cells and avoid other cell types as much as possible. One of the primary areas of active engineering is the specificity of targets, which can have unanticipated effects if delivered off-target. 
• Durability: Reprogramming occurs within the body and not in a controlled laboratory setting, making it difficult to estimate the duration of CAR-T cells' stay in the body or how stable it will be between patients. This is one of the key questions that the field has yet to solve. 
• Safety Monitoring: With ex vivo CAR-T, clinicians can test the manufactured cell product for quality before it's ever infused. In in-vivo approaches, that quality check, which is so crucial, occurs after the genetic material is actually delivered to the patient, and thus the safety monitoring has to be designed differently and to a large extent anew. 
• Regulatory Evidence Bar: All CAR-T products that have been approved to date have done so based on single arm trials, where all participants received the drug, and no control group. In 2026, FDA officials published in JAMA that the expectation for the future should be that cell-therapy approvals would generally require randomized trials against standard-of-care treatments, which is a higher standard that would be expected for in vivo candidates as well as conventional ones. This remains to be seen if that will still be the case as agency leadership transitions. At the same time, the UK will be updating its clinical trial regulations to the April 2026 to include speedier and risk-proportionate approval pathways, making it an appealing place to conduct exactly this type of early-phase trial.  
• Solid Tumors: Nearly all current, whether in vivo or in vitro, CAR-T successes are in blood cancers. Solid tumors on the other hand, they're a much tougher challenge: physical barriers, an inhospitable local immune environment and fewer clean surface markers to target. Being injected into a live cell is not a complete fix.

Read More Predicting Human Genetic Variants in Mice: A Game Changer for Genomic Research

Where It Fits in Cancer Care

Surgery, radiation, and chemotherapy remain the backbone of cancer treatment, and that isn't going to change soon. CAR-T therapy, in vivo or ex vivo, is a targeted addition to that toolkit, not a replacement for it. Weighing in vivo CAR-T vs traditional CAR-T therapy, the two would likely be understood as different generations of the same idea: the first generation proved that engineered immune cells could cure cancers that had run out of options; if in vivo approaches mature, the second generation is trying to make that same biology practical to deliver at scale.

Beyond Cancer

The concept of targeting immune cells directly within the body is not cancer-specific. Researchers are already speculating about other potential uses for the technology, including in the fight against autoimmune diseases, where in vivo CAR-T therapy, in theory, could attack and destroy misfiring immune cells that lead to autoimmune diseases such as lupus instead of the cancer cells the technology was initially created to combat. The applications are also longer term areas of interest, such as chronic infections and age-related immune decline, although they are less advanced than the oncology programs above.

Common Misconceptions 

In vivo CAR-T is already an approved treatment: It is not. All in vivo candidates mentioned in this report are in early phase clinical trials. No one has gotten regulatory approval in the world. 

It will be much more affordable from the outset: Costs should be lower without the manufacturing step, but the actual cost of any future approved therapy (as well as the actual cost of production of the vector) will depend on a number of other factors which have yet to be determined, including the frequency of dosing and market factors.

It's the same as a vaccine: In vivo CAR-T is similar to the mRNA vaccine delivery approach, but is used for a different purpose: to permanently reprogram a patient's own T cells to target cancer, rather than training the immune system to recognize a pathogen.

STEMEPEDIA Expert Insight

So far, the most compelling evidence for in vivo CAR-T is the small, uncontrolled early phase trials that were encouraging but so far not definitive enough to persuade regulators or oncologists. Whether or not in vivo reprogramming is possible in general is not likely to be the most important variable in the field's near-term future, since the initial trials indicate it is possible, but rather whether the cells' responses are persistent and whether those responses can be delivered with sufficient precision to meet the requirements of safety regulators who are raising their expectations regarding standards of evidence.

Read More Moringa: The Hidden Secret Behind Natural Energy, Beauty, and Healing

Conclusion

In vivo CAR-T is no longer a vision for the future; there is early clinical evidence and some of this evidence is positively promising. Encouraging does not equal proven. What is being tested these days is a small scale, what is being followed up is a short time, and what is being asked by the regulators is a harder question, not an easier one. It's clear that the field has shifted from whether this is possible, to how effective it is and how long it lasts, and this is the type of question that can only be answered by larger, longer trials. Having gained significant momentum in recent years, the next 2-3 years of data is likely to decide if in vivo CAR-T can be the scalable and easy-to-access form of cell therapy that the developers are striving for, and one of the more well watched lines of cancer immunotherapy innovation.

Frequently Asked Questions

Is in vivo CAR-T available to patients yet?

No. At this point it is only available in clinical trials and patients would have to be eligible for and participate in one of these trials.

How is in vivo CAR-T different from standard CAR-T?

In the standard CAR-T approach, a patient's T-cells are harvested, then genetically modified in the lab and then introduced back into the patient. In vivo CAR-T puts the genetic instruction into the patient's bloodstream, but doesn't remove T cells from the bloodstream.

What delivery methods are being used?

There are two main strategies: lipid nanoparticles, like mRNA vaccines, and engineered viral vectors, usually modified lentiviral vectors that target T cells specifically.

Does in vivo CAR-T require chemotherapy first?

Not necessarily. A small amount of early trial data indicates it may be effective without the lympho-depleting chemotherapy historically needed by traditional CAR-Ts, depending on the trial and platform.

Which cancers are being studied?

The current trials are for blood cancers such as multiple myeloma, B-cell lymphoma, and leukemia. Solid tumors are still a far greater challenge and are not a prime target for in vivo programs.

What are the side effects of in vivo CAR-T therapy?

The major safety issue is delivery accuracy, which means that the gene-carrying vector should only deliver the genes to T cells and not to other cell types in the body.

Can in vivo CAR-T treat autoimmune disease or other conditions?

The researchers are looking for other uses in autoimmune conditions, but these programs are much less advanced than their cancer counterparts.

When will in vivo CAR-T be approved by the FDA?

A definite timeframe for this is not yet available. With the current state of trials and a regulatory landscape that is increasingly favororing RCTs as evidence, approval if it occurs will likely happen only after the end of this decade.

Which companies are developing in vivo CAR-T therapy?

There are currently three companies that are doing the bulk of the work: Kelonia Therapeutics, Umoja Biopharma and Interius BioTherapeutics, with academic programs in China and Australia conducting early-stage trials.